Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Member Adherence to a Health Insurer-Sponsored Gap Closure Program Using Multi-Target Stool DNA Test for Colorectal Cancer Screening.
J Prim Care Community Health
December 2024
Exact Sciences Corporation, Madison, WI, USA.
Objectives: To describe member adherence to a mail-based, health insurer-sponsored gap closure program for colorectal cancer (CRC) screening using multi-target stool DNA (mt-sDNA; Cologuard) tests.
Methods: Combined patient data from Exact Sciences Laboratories LLC and data from mass-mailed mt-sDNA orders placed by a large Medicare Advantage Insurance Plan were analyzed (03/01/2023-06/30/2023). Adherence and time to test return were the primary and secondary outcomes, respectively.
The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy.
J Gastrointest Cancer
October 2024
Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA.
Background: Multitarget stool DNA (MT-sDNA) tests (here, Cologuard®) are currently used in average-risk patients as a primary method of screening for colorectal cancer. However, MT-sDNA testing has also been used in patients who previously underwent colonoscopy who wish to avoid repeat colonoscopy. Here, in a large primary care practice setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing in patients with a previously normal colonoscopy.
View Article and Find Full Text PDFIncreasing digital equity to promote online smoking cessation program engagement among rural adults: a randomized controlled pilot trial.
Commun Med (Lond)
October 2024
Department of Psychiatry & Psychology, Behavioral Health Research Program, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
Article Synopsis
- The study investigates digital access interventions designed to enhance engagement with an online smoking cessation program among rural adults, who generally have lower access to such resources.
- A pilot trial involved 90 rural smokers aged 18 and older, where participants were randomized into three groups: a control group with print materials, a group with a loaner iPad, and a group with the iPad plus coaching calls.
- Results indicated no significant differences in overall engagement among groups, but the group receiving coaching showed greater improvements in smoking cessation outcomes and had positive feedback about the intervention.
Barriers and proposed solutions to at-home colorectal cancer screening tests in medically underserved health centers across three US regions to inform a randomized trial.
Cancer Med
August 2024
Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Introduction: At-home colorectal cancer (CRC) screening is an effective way to reduce CRC mortality, but screening rates in medically underserved groups are low. To plan the implementation of a pragmatic randomized trial comparing two population-based outreach approaches, we conducted qualitative research on current processes and barriers to at-home CRC screening in 10 community health centers (CHCs) that serve medically underserved groups, four each in Massachusetts and California, and two tribal facilities in South Dakota.
Methods: We conducted 53 semi-structured interviews with clinical and administrative staff at the participating CHCs.
Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
Gastroenterology
July 2024
Division of Gastroenterology and Hepatology, Oregon Health and Sciences University, Portland, Oregon.
Article Synopsis
- Colorectal cancer (CRC) screening is effective but underutilized; blood-based tests could enhance participation by overcoming barriers associated with traditional screening methods.* -
- A study comparing blood-based tests to established methods (like multi-target stool DNA, FIT, and colonoscopy) found that while a blood test meeting CMS standards reduces CRC incidence and mortality, it is less effective and more costly than these alternatives.* -
- For blood-based tests to be a viable substitute for traditional screening methods, they need to achieve higher sensitivity for CRC and advanced precancerous lesions (APL) to match or exceed the participation rates and effectiveness of current tests.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!